The DOI matches its Crossref record; 65 of the 65 references it cites were found in a registry or an index.
Lack of Treatment Persistence and Treatment Nonadherence as Barriers to Glycaemic Control in Patients with Type 2 Diabetes
Open accessAbstract
Treatment persistence (continuing to take medication for the prescribed period) and treatment adherence (complying with the prescription in terms of drug schedules and dosage) are both important when treating chronic diseases such as type 2 diabetes (T2D). They can be indicators of patient satisfaction with treatment. In T2D, the achievement of optimal outcomes requires both persistence with and adherence to prescribed therapy. Poor persistence with and adherence to T2D medication can have profound consequences for the patient, including non-achievement of glycaemic goals and an increased risk of long-term complications and mortality. Therefore, poor treatment persistence and adherence may also have economic consequences, including increased healthcare resource utilization and healthcare costs. Treatment persistence and adherence are affected by several factors, including the mode of administration, administration frequency/regimen complexity, and patient expectations. The aims of this review are as follows: to provide an overview of persistence with and adherence to different antidiabetes therapies for patients with T2D in the real-world setting; examine factors contributing to poor treatment persistence and adherence; and assess available data on the impact of poor treatment persistence and/or adherence on clinical and economic outcomes. Numerous potential targets for improving treatment persistence and/or adherence are identified, including developing less complex treatment regimens with lower pill burdens or less frequent injections, improving the convenience of drug-delivery systems, such as the use of insulin pen devices rather than the conventional vial and syringe, and developing therapies with an improved safety profile to alleviate patient fears of adverse effects, such as weight gain and risk of hypoglycaemia.Funding: Sanofi.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Lack of adherence and persistence with treatment in T2DM acts as a barrier to achieving glycaemic control [6], increases the risk of microvascular and macrovascular complications [7], and increases healthcare costs [5, 8].”
In the citing paper
“In people with T2DM who discontinue or do not properly adhere to their therapy, there is an increased risk of microvascular and macrovascular complications [7], which can in turn increase healthcare costs further [5, 6].”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2015) · Diabetes Care · doi:10.2337/dc14-2441 · Cited by 3,066
Medication compliance and persistence: terminology and definitions
Cramer, J. A., Roy, A., Burrell, A., Fairchild, C. J., Fuldeore, M. J., Ollendorf, D. A., & Wong, P. K. (2008) · Value in Health · doi:10.1111/j.1524-4733.2007.00213.x · Cited by 2,220
Impact of Medication Adherence on Hospitalization Risk and Healthcare Cost
Sokol, M. C., McGuigan, K. A., Verbrugge, R. R., & Epstein, R. S. (2005) · Medical Care · doi:10.1097/01.mlr.0000163641.86870.af · Cited by 1,729
Adherence to Therapies in Patients with Type 2 Diabetes
García‐Pérez, L., Álvarez, M., Dilla, T., Gil-Guillén, V. F., & Orozco‐Beltrán, D. (2013) · Diabetes Therapy · doi:10.1007/s13300-013-0034-y · Cited by 783
Nicolucci, A., Kovacs Burns, K., Holt, R. I. G., Comaschi, M., Hermanns, N., Ishii, H., Kokoszka, A., Pouwer, F., Skovlund, S. E., Stuckey, H., et al. (2013) · Diabetic Medicine · doi:10.1111/dme.12245 · Cited by 739
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M. A., Peters, A. L., Τσάπας, Α., Wender, R. C., & Matthews, D. R. (2015) · Diabetologia · doi:10.1007/s00125-014-3460-0 · Cited by 701
Peyrot, M., Barnett, A. H., Meneghini, L. F., & Schumm‐Draeger, P. ‐. (2012) · Diabetic Medicine · doi:10.1111/j.1464-5491.2012.03605.x · Cited by 655
Davies, M. J., Gagliardino, J. J., Gray, L. J., Khunti, K., Mohan, V., & Hughes, R. (2013) · Diabetic Medicine · doi:10.1111/dme.12128 · Cited by 302
American Diabetes Association (2016) · Diabetes Care · doi:10.2337/dc17-s009 · Cited by 279
Lee, W. C., Balu, S., Cobden, D., Joshi, A. V., & Pashos, C. L. (2006) · Clinical Therapeutics · doi:10.1016/j.clinthera.2006.10.004 · Cited by 262
The Impact of Treatment Noncompliance on Mortality in People With Type 2 Diabetes
Currie, C. J., Peyrot, M. F., Morgan, C. L., Poole, C., Jenkins‐Jones, S., Rubin, R. R., Burton, C. M., & Evans, M. (2012) · Diabetes Care · doi:10.2337/dc11-1277 · Cited by 261
Association between adherence to pharmacotherapy and outcomes in type 2 diabetes: a meta-analysis
Khunti, K., Seidu, S., Kunutsor, S., & Davies, M. (2017) · Diabetes Care · doi:10.2337/dc16-1925 · Cited by 231
Adherence to insulin and its association with glycaemic control in patients with type 2 diabetes
Donnelly, L. A., Morris, A. D., & Evans, J. M. M. (2007) · QJM · doi:10.1093/qjmed/hcm031 · Cited by 228
Martin, B. C., Wiley-Exley, E. K., Richards, S., Domino, M. E., Carey, T. S., & Sleath, B. L. (2009) · Annals of Pharmacotherapy · doi:10.1345/aph.1k671 · Cited by 226
Herman, W. H. (2015) · Diabetes Care · doi:10.2337/dc15-1773 · Cited by 209
Impact of Fixed-Dose Combination Drugs on Adherence to Prescription Medications
Pan, F., Chernew, M. E., & Fendrick, A. M. (2008) · Journal of General Internal Medicine · doi:10.1007/s11606-008-0544-x · Cited by 157
Carls, G. S., Tuttle, E., Tan, R.-D., Huynh, J., Yee, J., Edelman, S. V., & Polonsky, W. H. (2017) · Diabetes Care · doi:10.2337/dc16-2725 · Cited by 153
Measuring beliefs about taking hypoglycaemic medication among people with Type 2 diabetes
Farmer, A. A., Kinmonth, A. L., & Sutton, S. R. (2005) · Diabetic Medicine · doi:10.1111/j.1464-5491.2005.01778.x · Cited by 138
Longitudinal association between medication adherence and glycaemic control in Type 2 diabetes
Aikens, J. E., & Piette, J. D. (2012) · Diabetic Medicine · doi:10.1111/dme.12046 · Cited by 123
Buysman, E. K., Liu, F., Hammer, M., & Langer, J. (2015) · Advances in Therapy · doi:10.1007/s12325-015-0199-z · Cited by 101
Lopez, J., Annunziata, K., Bailey, R., Morisky, D. E., & Rupnow, M. (2014) · Patient Preference and Adherence · doi:10.2147/ppa.s58813 · Cited by 96
Kostev, K., Ouwens, M., Grandy, S., Johnsson, K. M., & Qiao, Q. (2016) · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy · doi:10.2147/dmso.s99732 · Cited by 92
Shiyanbola, O. O., Unni, E., Huang, Y., & Lanier, C. (2017) · Research in Social and Administrative Pharmacy · doi:10.1016/j.sapharm.2017.12.005 · Cited by 82
Yavuz, D. G., Özcan, S., & Deyneli, O. (2015) · Patient Preference and Adherence · doi:10.2147/ppa.s87935 · Cited by 80
Bron, M., Marynchenko, M. B., Yang, H., Yu, A. P., & Wu, E. Q. (2012) · Postgraduate Medicine · doi:10.3810/pgm.2012.01.2525 · Cited by 78
Brod, M., Rana, A., & Barnett, A. H. (2012) · Current Medical Research and Opinion · doi:10.1185/03007995.2012.743458 · Cited by 77
Walz, L., Pettersson, B., Rosenqvist, U., Deleskog, A., Journath, G., & Wändell, P. (2014) · Patient Preference and Adherence · doi:10.2147/ppa.s58781 · Cited by 75
DiBonaventura, M., Wintfeld, N., Huang, J., & Goren, A. (2014) · Patient Preference and Adherence · doi:10.2147/ppa.s55550 · Cited by 70
(2017) · Diabetes Care · doi:10.2337/dc17-er07a · Cited by 62
Does prescription drug adherence reduce hospitalizations and costs? The case of diabetes
Encinosa, W. E., Bernard, D., & Dor, A. (2010) · Advances in health economics and health services research · doi:10.1108/s0731-2199(2010)0000022010 · Cited by 61
He, X., Chen, L., Wang, K., Wu, H., & Wu, J. H. (2017) · Patient Preference and Adherence · doi:10.2147/ppa.s123389 · Cited by 60
Medication Adherence Affects Risk of New Diabetes Complications
Simpson, S. H., Mu, L., & Eurich, D. T. (2016) · Annals of Pharmacotherapy · doi:10.1177/1060028016653609 · Cited by 57
Real-World Insulin Treatment Persistence among Patients with Type 2 Diabetes
Wei, W., Pan, C., Xie, L., & Başer, O. (2013) · Endocrine Practice · doi:10.4158/ep13159.or · Cited by 56
Nau, D. P. (2012) · PubMed · Cited by 54
Lokhandwala, T., Smith, N., Sternhufvud, C., Sörstadius, E., Lee, W. C., & Mukherjee, J. (2015) · Journal of Medical Economics · doi:10.3111/13696998.2015.1109518 · Cited by 53
Preferences for medication attributes among patients with type 2 diabetes mellitus in the UK
Gelhorn, H. L., Stringer, S. M., Brooks, A. B., Thompson, C., Monz, B. U., Boye, K. S., Hach, T., Lund, S. S., & Palencia, R. (2013) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12091 · Cited by 52
Basal Insulin Intensification in Patients with Type 2 Diabetes: A Review
Meece, J. D. (2018) · Diabetes Therapy · doi:10.1007/s13300-018-0395-3 · Cited by 51
Early Discontinuation and Restart of Insulin in the Treatment of Type 2 Diabetes Mellitus
Ascher‐Svanum, H., Lage, M. J., Perez‐Nieves, M., Reaney, M. D., Lorraine, J., Rodríguez, Á., & Treglia, M. (2014) · Diabetes Therapy · doi:10.1007/s13300-014-0065-z · Cited by 50
Predictors of non-adherence to pharmacotherapy in patients with type 2 diabetes
Jarab, A. S., Almrayat, R., Alqudah, S., Thehairat, E., Mukattash, T. L., Khdour, M. R., & Pinto, S. (2014) · International Journal of Clinical Pharmacy · doi:10.1007/s11096-014-9938-5 · Cited by 49
Banerji, M. A., & Dunn, J. D. (2013) · PubMed Central · Cited by 46
Chandran, A., Bonafede, M. K., Nigam, S., Saltiel-Berzin, R., Hirsch, L. J., & Lahue, B. J. (2015) · PubMed Central · Cited by 44
Refill Adherence to Oral Hypoglycemic Agents and Glycemic Control in Veterans
Kim, N. V., Agostini, J. V., & Justice, A. C. (2010) · Annals of Pharmacotherapy · doi:10.1345/aph.1m570 · Cited by 38
Blüher, M., Kurz, I., Dannenmaier, S., & Dworak, M. (2015) · Clinical Diabetes · doi:10.2337/diaclin.33.2.55 · Cited by 37
GLP-1 RA Treatment Patterns Among Type 2 Diabetes Patients in Five European Countries
Divino, V. M., DeKoven, M., Khan, F. A., Boye, K. S., Sapin, H., & Norrbacka, K. (2017) · Diabetes Therapy · doi:10.1007/s13300-016-0224-5 · Cited by 36
Başer, O., Tangirala, K., Wei, W., & Xie, L. (2013) · ClinicoEconomics and Outcomes Research · doi:10.2147/ceor.s49279 · Cited by 35
Outcomes and Treatment Patterns of Adding a Third Agent to 2 OADs in Patients with Type 2 Diabetes
LEVIN, P. A., Wei, W., Zhou, S., Xie, L., & Başer, O. (2014) · Journal of Managed Care Pharmacy · doi:10.18553/jmcp.2014.20.5.501 · Cited by 34
The multinational second Diabetes, Attitudes, Wishes and Needs study: results of the French survey
Reach, G., Consoli, S. M., Colas, C., Duclos, M., Fontaine, P., Martineau, C., Avril, C., Pucheu, S., Brunet, O., Halimi, S., et al. (2015) · Patient Preference and Adherence · doi:10.2147/ppa.s68941 · Cited by 34
Venditti, E. M., Tan, K., CHANG, N. T., Laffel, L. M., McGinley, G., Miranda, N., Tryggestad, J. B., Walders‐Abramson, N., Yasuda, P. M., & Delahanty, L. M. (2018) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2018.02.001 · Cited by 34
A real-world study of patients with type 2 diabetes initiating basal insulins via disposable pens
Xie, L., Wei, W., Pan, C., Du, J., & Başer, O. (2011) · Advances in Therapy · doi:10.1007/s12325-011-0074-5 · Cited by 32
Roussel, R., Charbonnel, B. H., Behar, M., Gourmelen, J., Emery, C., & Detournay, B. (2016) · Diabetes Therapy · doi:10.1007/s13300-016-0185-8 · Cited by 32
Mashitani, T., Hayashino, Y., Okamura, S., Kitatani, M., Furuya, M., Matsunaga, S., Kuwata, H., Tsujii, S., & Ishii, H. (2013) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2013.03.006 · Cited by 31
Mashitani, T., Hayashino, Y., Okamura, S., Kitatani, M., Furuya, M., Iburi, T., Kuwata, H., Tsujii, S., & Ishii, H. (2015) · Acta Diabetologica · doi:10.1007/s00592-015-0725-0 · Cited by 30
Liraglutide Versus Exenatide Once Weekly: Persistence, Adherence, and Early Discontinuation
Yu, M. B., Xie, J., Landó, L. F., Kabul, S., & Swindle, R. W. (2015) · Clinical Therapeutics · doi:10.1016/j.clinthera.2015.11.017 · Cited by 30
Carls, G. S., Tan, R., Zhu, J., Tuttle, E., Yee, J., Edelman, S. V., & Polonsky, W. H. (2017) · Obesity Science & Practice · doi:10.1002/osp4.116 · Cited by 28
Jermendy, G., Kiss, Z., Rokszin, G., Abonyi‐Tóth, Z., Wittmann, I., & Kempler, P. (2018) · Diabetes Therapy · doi:10.1007/s13300-018-0483-4 · Cited by 28
Wei, W., Zhou, S., Miao, R., Pan, C., Xie, L., Başer, O., & Gill, J. (2014) · Advances in Therapy · doi:10.1007/s12325-014-0120-1 · Cited by 24
Pscherer, S., Chou, E., Dippel, F. W., Rathmann, W., & Kostev, K. (2015) · Primary care diabetes · doi:10.1016/j.pcd.2015.01.011 · Cited by 23
Miao, R., Wei, W., Lin, J., Xie, L., & Başer, O. (2014) · Journal of Diabetes Science and Technology · doi:10.1177/1932296813516956 · Cited by 22
Downie, M. R., Kilov, G., & Wong, J. (2016) · Diabetes Therapy · doi:10.1007/s13300-016-0199-2 · Cited by 20
Miao, R., Wei, W., Başer, O., & Xie, L. (2013) · Patient Preference and Adherence · doi:10.2147/ppa.s49287 · Cited by 15
Anderten, H., Dippel, F. W., & Kostev, K. (2015) · Journal of Diabetes Science and Technology · doi:10.1177/1932296814566232 · Cited by 14
Gatwood, J. D., Chisholm‐Burns, M. A., Davis, R. L., Thomas, F., Potukuchi, P. K., Hung, A. M., & Kovesdy, C. P. (2018) · Diabetic Medicine · doi:10.1111/dme.13775 · Cited by 14
BAJAJ, H. S., Ye, C., Jain, E., Venn, K., Stein, E., & Aronson, R. (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13040 · Cited by 12
Ampudia‐Blasco, F. J., Galán, M., & Brod, M. I. (2014) · Endocrinología y Nutrición · doi:10.1016/j.endonu.2014.03.008 · Cited by 10
Different Insulin Initiation Regimens in Patients with Type 2 Diabetes - A Review Article
Mudassir, A. M., Thida, A. K., Meela, A., Eligar, V. S., Js, D., & Madelein, Y. (2018) · International Journal of Diabetes and Clinical Research · doi:10.23937/2377-3634/1410083 · Cited by 5
Research works printed but not linked: 1
- Reynolds SL, Zhou S, Uribe C, Li Y. Impact of insulin delivery systems in elderly patients with type 2 diabetes. Am J Pharm Benefits. 2015;7:222–31.
Cited by
Sorted by citations
Evolution of Insulin Delivery Devices: From Syringes, Pens, and Pumps to DIY Artificial Pancreas
Kesavadev, J., Saboo, B., Krishna, M. B., & Krishnan, G. (2020) · Diabetes Therapy · doi:10.1007/s13300-020-00831-z · Cited by 221
Okada, M., Mitchell, P., Finger, R. P., Eldem, B. M., Talks, J. S., Hirst, C., Paladini, L. M., Barratt, J., Wong, T. Y., & Loewenstein, A. (2020) · Ophthalmology · doi:10.1016/j.ophtha.2020.07.060 · Cited by 212
Recent Advances in Incretin-Based Pharmacotherapies for the Treatment of Obesity and Diabetes
Tan, Q., Akindehin, S. E., Orsso, C. E., Waldner, R. C., DiMarchi, R. D., Müller, T. D., & Haqq, A. M. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.838410 · Cited by 146
Evans, M., Engberg, S., Faurby, M. D., Fernandes, J. D. D. R., Hudson, P., & Polonsky, W. H. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14603 · Cited by 105
Polonsky, W. H., ARORA, R., Faurby, M. D., Fernandes, J. D. D. R., & Liebl, A. (2021) · Diabetes Therapy · doi:10.1007/s13300-021-01189-6 · Cited by 85
Metadata
- Authors
- Guerci, B., Chanan, N., Kaur, S., Jasso-Mosqueda, J. G., & Lew, E.
- Affiliations
- Inserm (FR)
- Sanofi (France) (FR)
- Corresponding author
- Guerci, Bruno
- Venue
- Diabetes Therapy
- Published
- 2019-03-08
- Volume
- 10
- Issue
- 2
- Pages
- 437-449
- ISSN
- 1869-6953 (ISSN-L)
- 1869-6961
- PMC
- PMC6437240
- OpenAlex
- W2922388296
- Cited by
- 106
- References
- 65
- Citations by year
- 2026: 10 · 2025: 17 · 2024: 11 · 2023: 12 · 2022: 16 · 2021: 23 · 2020: 14 · 2019: 3
- FWCI
- 3.56
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Diabetes Therapy (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Funders
- Sanofi
- Topics
- Health Sciences › Medicine › Family Practice › Medication Adherence and Compliance
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Education
- Keywords
- type 2 diabetes, treatment persistence, medication adherence, glycemic control, medication burden, insulin pen devices, drug delivery systems, patient expectations, adverse drug reactions, hypoglycemia, health care costs, real-world evidence
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
